These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27563818)

  • 21. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer.
    Xiang L; Rong G; Zhao J; Wang Z; Shi F
    Oncol Lett; 2018 May; 15(5):7769-7775. PubMed ID: 29731902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
    Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
    J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precursor lesions and prognostic factors in primary peritoneal serous carcinoma.
    Lee S; Nelson G; Duan Q; Magliocco AM; Duggan MA
    Int J Gynecol Pathol; 2013 Nov; 32(6):547-55. PubMed ID: 24071870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
    Russo A; Yang Z; Heyrman GM; Cain BP; Lopez Carrero A; Isenberg BC; Dean MJ; Coppeta J; Burdette JE
    Cancer Lett; 2022 Sep; 543():215779. PubMed ID: 35697329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo.
    Pereira M; Glogova A; Haagsma J; Stewart J; Shepherd TG; Petrik J
    J Ovarian Res; 2023 Nov; 16(1):218. PubMed ID: 37986175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
    Klotz DM; Wimberger P
    Arch Gynecol Obstet; 2017 Dec; 296(6):1055-1062. PubMed ID: 28940023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.
    Hatano Y; Fukuda S; Makino H; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2018 Apr; 13(1):24. PubMed ID: 29703236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumorigenesis and peritoneal colonization from fallopian tube epithelium.
    Eddie SL; Quartuccio SM; Ó hAinmhir E; Moyle-Heyrman G; Lantvit DD; Wei JJ; Vanderhyden BC; Burdette JE
    Oncotarget; 2015 Aug; 6(24):20500-12. PubMed ID: 25971410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular markers derived from ovarian cancer and its correlation with the types of oviductal epithelial lesions].
    Yuan Y; Zhu W; Gong G; Jiang J; Wang Y; Wu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 May; 44(5):528-534. PubMed ID: 31303616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.
    Wu R; Zhai Y; Kuick R; Karnezis AN; Garcia P; Naseem A; Hu TC; Fearon ER; Cho KR
    J Pathol; 2016 Nov; 240(3):341-351. PubMed ID: 27538791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
    Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; Long DT; Spruill L; Romeo MJ; Helke KL; Delaney JR
    bioRxiv; 2024 Jan; ():. PubMed ID: 38352443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer.
    Ó hAinmhire E; Quartuccio SM; Cheng W; Ahmed RA; King SM; Burdette JE
    PLoS One; 2014; 9(2):e89553. PubMed ID: 24586866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of
    Teng K; Ford MJ; Harwalkar K; Li Y; Pacis AS; Farnell D; Yamanaka N; Wang YC; Badescu D; Ton Nu TN; Ragoussis J; Huntsman DG; Arseneau J; Yamanaka Y
    Cancer Res; 2021 Oct; 81(20):5147-5160. PubMed ID: 34301761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer.
    Galhenage P; Zhou Y; Perry E; Loc B; Fietz K; Iyer S; Reinhardt F; Da Silva T; Botchkarev V; Chen J; Crum CP; Weinberg RA; Pathania S
    Cell Rep; 2023 Oct; 42(10):113144. PubMed ID: 37729060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.